Judit Matito

1.0k total citations
23 papers, 365 citations indexed

About

Judit Matito is a scholar working on Oncology, Cancer Research and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Judit Matito has authored 23 papers receiving a total of 365 indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Oncology, 13 papers in Cancer Research and 11 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Judit Matito's work include Cancer Genomics and Diagnostics (13 papers), Pancreatic and Hepatic Oncology Research (5 papers) and Advanced Breast Cancer Therapies (4 papers). Judit Matito is often cited by papers focused on Cancer Genomics and Diagnostics (13 papers), Pancreatic and Hepatic Oncology Research (5 papers) and Advanced Breast Cancer Therapies (4 papers). Judit Matito collaborates with scholars based in Spain, Palestinian Territory and United States. Judit Matito's co-authors include Ana Vivancos, Ginevra Caratù, Paolo Nucíforo, Héctor G. Pálmer, Oriol Arqués, Josep Tabernero, Stefania Landolfi, Rodrigo Dienstmann, Isabel Puig and Jordi Rodón and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Clinical Cancer Research.

In The Last Decade

Judit Matito

20 papers receiving 362 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Judit Matito Spain	9	218	208	97	72	63	23	365
Cristina Quero Spain	10	175 0.8×	133 0.6×	73 0.8×	86 1.2×	115 1.8×	19	367
Lars D. Engstrom United States	9	281 1.3×	204 1.0×	74 0.8×	48 0.7×	36 0.6×	22	434
Laia Perez‐Roca Spain	9	212 1.0×	137 0.7×	197 2.0×	124 1.7×	41 0.7×	11	393
Marcin Nicoś Poland	11	191 0.9×	170 0.8×	164 1.7×	157 2.2×	43 0.7×	43	417
Saravut J. Weroha United States	8	223 1.0×	136 0.7×	94 1.0×	85 1.2×	34 0.5×	19	349
Kelly A. Shimabukuro United States	9	171 0.8×	132 0.6×	94 1.0×	120 1.7×	61 1.0×	17	353
Heather A. Hirsch United States	9	234 1.1×	235 1.1×	69 0.7×	39 0.5×	36 0.6×	19	420
Trine Lindsted United States	7	208 1.0×	254 1.2×	158 1.6×	91 1.3×	52 0.8×	10	439
Toby Roe United Kingdom	4	195 0.9×	116 0.6×	77 0.8×	99 1.4×	33 0.5×	7	302
Hidenori Kitai Japan	8	232 1.1×	150 0.7×	89 0.9×	52 0.7×	32 0.5×	16	330

Countries citing papers authored by Judit Matito

Since Specialization

Citations

This map shows the geographic impact of Judit Matito's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Judit Matito with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Judit Matito more than expected).

Fields of papers citing papers by Judit Matito

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Judit Matito. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Judit Matito. The network helps show where Judit Matito may publish in the future.

Co-authorship network of co-authors of Judit Matito

This figure shows the co-authorship network connecting the top 25 collaborators of Judit Matito. A scholar is included among the top collaborators of Judit Matito based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Judit Matito. Judit Matito is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Matito, Judit, María Quindós, Claudia Valverde, et al.. (2025). Targeted Next-Generation Sequencing in Succinate Dehydrogenase–Deficient GI Stromal Tumor Identifies Actionable Alterations in the PI3K/mTOR Pathway. JCO Precision Oncology. 9(9). e2400497–e2400497.

Papakonstantinou, Andri, Adrià López‐Fernández, Judit Matito, et al.. (2025). Identifying germline pathogenic variants in breast cancer using tumor sequencing. The Breast. 81. 104439–104439. 1 indexed citations

Vila-Casadesús, María, Tian V. Tian, Florian Castet, et al.. (2024). Clinical Value of Liquid Biopsy in Patients with FGFR2 Fusion–Positive Cholangiocarcinoma During Targeted Therapy. Clinical Cancer Research. 30(19). 4491–4504. 13 indexed citations

Chiaravalli, Marta, Anthony Turpin, Florian Castet, et al.. (2023). Clinical and genomic characterization of pancreatic ductal adenocarcinoma patients with lung oligometastasis. SHILAP Revista de lepidopterología. 2. 100011–100011.

Moretto, Roberto, Marco Maria Germani, Javier Ros, et al.. (2023). Predictive Impact of RNF43 Mutations in Patients With Proficient Mismatch Repair/Microsatellite Stable BRAFV600E-Mutated Metastatic Colorectal Cancer Treated With Target Therapy or Chemotherapy. JCO Precision Oncology. 7(7). e2300255–e2300255. 5 indexed citations

Marín‐Aguilera, Mercedes, Pedro Jares, Guillermo Villacampa, et al.. (2023). 13P Analytical validation of HER2DX test for early-hER2+ breast cancer. ESMO Open. 8(1). 101237–101237. 1 indexed citations

Ros, Javier, Judit Matito, Guillermo Villacampa, et al.. (2023). Plasmatic BRAF-V600E allele fraction as a prognostic factor in metastatic colorectal cancer treated with BRAF combinatorial treatments. Annals of Oncology. 34(6). 543–552. 38 indexed citations

Matito, Judit, Ágatha Martín, Helena Verdaguer, et al.. (2022). KRAS mutation detection and cfDNA in liquid biopsy as prognostic factors in pancreatic adenocarcinoma.. Journal of Clinical Oncology. 40(16_suppl). e16302–e16302. 1 indexed citations

Papakonstantinou, Andri, Judit Matito, Meritxell Bellet, et al.. (2022). Utility of liquid biopsy for identifying emerging mutations (mut) and novel treatment options in luminal metastatic breast cancer (LMBC).. Journal of Clinical Oncology. 40(16_suppl). 1061–1061. 1 indexed citations

10.

Saura, Cristina, Judit Matito, Mafalda Oliveira, et al.. (2021). Biomarker Analysis of the Phase III NALA Study of Neratinib + Capecitabine versus Lapatinib + Capecitabine in Patients with Previously Treated Metastatic Breast Cancer. Clinical Cancer Research. 27(21). 5818–5827. 15 indexed citations

11.

Elez, Élena, Javier Ros, Giulia Martini, et al.. (2021). LBA-3 Integrated analysis of cell-free DNA (cfDNA) BRAF mutant allele fraction (MAF) and whole exome sequencing in BRAFV600E metastatic colorectal cancer (mCRC) treated with BRAF-antiEGFR +/- MEK inhibitors. Annals of Oncology. 32. S226–S227. 10 indexed citations

12.

Martínez‐Martí, Alex, Enriqueta Felip, Francesco M. Mancuso, et al.. (2021). Genetic evolution to tyrosine kinase inhibitory therapy in patients with EGFR-mutated non-small-cell lung cancer. British Journal of Cancer. 125(11). 1561–1569. 6 indexed citations

13.

Verdaguer, Helena, Francesco M. Mancuso, Daniel Acosta, et al.. (2020). DNA damage repair (DDR) gene mutations (mut) are predictors of response to platinum-based chemotherapy in advanced pancreatic cancer (PC) patients (pts).. Journal of Clinical Oncology. 38(15_suppl). e16805–e16805.

14.

Saura, Cristina, Ana Vivancos, Judit Matito, et al.. (2020). 1O Neratinib + capecitabine vs lapatinib + capecitabine in HER2+ metastatic breast cancer previously treated with ≥2 HER2-directed regimens: Exploratory biomarker analyses from phase III NALA trial. Annals of Oncology. 31. S15–S15. 6 indexed citations

15.

Capdevila, Jaume, Oriol Arqués, José Ramón Hernández Mora, et al.. (2019). Epigenetic EGFR Gene Repression Confers Sensitivity to Therapeutic BRAFV600E Blockade in Colon Neuroendocrine Carcinomas. Clinical Cancer Research. 26(4). 902–909. 28 indexed citations

16.

Oliveira, Mafalda, Judit Matito, Raquel Pérez-López, et al.. (2019). Determinants of concordance in clinically relevant genes (CRG) from synchronously acquired tumor biopsies (tBx) and ctDNA in metastatic breast cancer (MBC).. Journal of Clinical Oncology. 37(15_suppl). 1075–1075. 1 indexed citations

17.

Martínez‐Martí, Alex, Enriqueta Felip, Judit Matito, et al.. (2017). DualMET andERBB inhibition overcomes intratumor plasticity in osimertinib-resistant-advanced non-small-cell lung cancer (NSCLC). Annals of Oncology. 28(10). 2451–2457. 55 indexed citations

18.

Vivancos, Ana, Héctor G. Pálmer, Judit Matito, et al.. (2016). Analysis of RSPO gene expression in solid tumors.. Journal of Clinical Oncology. 34(15_suppl). e23235–e23235. 1 indexed citations

19.

Arqués, Oriol, Irene Chicote, Isabel Puig, et al.. (2015). Tankyrase Inhibition Blocks Wnt/β-Catenin Pathway and Reverts Resistance to PI3K and AKT Inhibitors in the Treatment of Colorectal Cancer. Clinical Cancer Research. 22(3). 644–656. 147 indexed citations

20.

Vivancos, Ana, Ginevra Caratù, Judit Matito, et al.. (2015). Genetic evolution of nevus of Ota reveals clonal heterogeneity acquiring BAP1 and TP53 mutations. Pigment Cell & Melanoma Research. 29(2). 247–253. 16 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact